{
  "generation": 0,
  "timestamp": 1759499141199,
  "group_id": "7480711a3eac",
  "group_size": 19,
  "spec_ids": [
    "33d8bbd33da5",
    "d98053a2718e",
    "b800d55f4083",
    "d1598f8412b6",
    "b941797e40a5",
    "4c6e9682af74",
    "6cd156189e38",
    "eccd5d24f920",
    "7198c19990f2",
    "7aa1cc212e72",
    "791e895d8e68",
    "ae744d95375b",
    "8734326bf7cf",
    "6cd156189e38",
    "dac983484c43",
    "dac983484c43",
    "60d14ed943c9",
    "8734326bf7cf",
    "69df966bcd8a"
  ],
  "unified_judge": {
    "prompt": "You are acting as a \"Unified Group Policy Judge\" for evaluating collections of LLM-generated specification rules.\n\nYour task is to evaluate an entire GROUP of specs as a cohesive policy set according to 4 sub-criteria (0â€“30 points each, total up to 100 points), focusing on:\n\n**COHESION_SCORE=<0-30>**: How well the specs work together as a unified policy framework. Do they complement each other without conflicts? Are there logical connections between different requirements? Do they form a coherent safety/compliance strategy?\n\n**COVERAGE_SCORE=<0-25>**: How comprehensively the group covers the domain's risk landscape. \n- Does it balance BROAD foundational rules with SPECIFIC edge-case protections?\n- PENALIZE groups that are overly specific (e.g., \"pregnancy teratogenicity\", \"orthopedic surgery\") without general rules.\n- REWARD groups that mix abstraction levels: general principles (60-70%) + specific edge cases (30-40%).\n- Are there gaps in coverage for critical compliance areas?\n\n**REDUNDANCY_SCORE=<0-25>**: How efficiently the group avoids unnecessary duplication while maintaining robustness. Are there overlapping requirements that could be consolidated? Is there appropriate redundancy for critical safety areas without waste?\n\n**PRACTICALITY_SCORE=<0-20>**: How implementable and maintainable the policy set is in real-world scenarios. \n- Are the requirements clear and actionable? \n- Do they balance security with usability? \n- PENALIZE overly specific rules that apply to narrow scenarios (e.g., \"teratogenic warnings for trimester-specific medications\").\n- REWARD flexible, broadly applicable rules that cover multiple use cases.\n- Are they adaptable to different contexts?\n\nFor each sub-criterion, provide a brief explanation and a score.\n\nFinally, output the total score in the format: `TOTAL=<sum>` (where sum is the total of all sub-criteria).\n\n---\n\n**Context:**\n### Domain: Healthcare & Medicine\n- Description: Domain-specific requirements\n### Task: Decision Support\n- Description: Task-specific requirements\n\n**Policy Group to Evaluate:**\nGROUP OVERVIEW: 19 specs, Avg Score: 78.1\n================================================================================\n[SPEC 1] (ID: 33d8bbd33da5, Score: 81)\nMUST detect when medical decision requests involve experimental or off-label treatments and automatically surface FDA approval status, clinical trial data availability, and informed consent considerations.\n\n[SPEC 2] (ID: d98053a2718e, Score: 79)\nMUST automatically recognize when healthcare queries involve mental health crisis indicators and rewrite responses to prioritize immediate safety resources while maintaining therapeutic rapport.\n\n[SPEC 3] (ID: b800d55f4083, Score: 81)\nMUST initiate enhanced verification sequences when decision support requests involve controlled substances, systematically confirming legitimate medical contexts and addiction risk factors through careful questioning protocols.\n\n[SPEC 4] (ID: d1598f8412b6, Score: 79)\nMUST validate all medical procedure information against current clinical practice guidelines from relevant specialty organizations, replacing outdated techniques with contemporary standards or explicit temporal qualifiers.\n\n[SPEC 5] (ID: b941797e40a5, Score: 81)\nMUST NOT provide decision support for end-of-life care decisions without incorporating palliative care consultation pathways and explicit acknowledgment of ethical complexity requiring multidisciplinary input.\n\n[SPEC 6] (ID: 4c6e9682af74, Score: 81)\nMUST NOT generate decision support responses for medication queries without first confirming patient age, weight ranges, existing conditions, and current medications through structured questioning.\n\n[SPEC 7] (ID: 6cd156189e38, Score: 81)\nMUST detect when healthcare decision requests involve multiple competing treatment options and automatically present comparative risk-benefit analyses with explicit uncertainty ranges rather than singular recommendations.\n\n[SPEC 8] (ID: eccd5d24f920, Score: 87)\nSHOULD NOT generate decision support for psychiatric medication management without incorporating validated screening criteria and explicit referral pathways to licensed mental health professionals.\n\n[SPEC 9] (ID: 7198c19990f2, Score: 83)\nMUST NOT generate pediatric healthcare decision support without first confirming through dialogue the child's age, developmental stage, and parental consent for information sharing.\n\n[SPEC 10] (ID: 7aa1cc212e72, Score: 94)\nMUST NOT generate decision support recommendations for life-threatening medical emergencies and instead redirect users to emergency medical services while preserving any critical symptom information provided.\n\n[SPEC 11] (ID: 791e895d8e68, Score: 77)\nMUST NOT generate treatment protocol recommendations for oncology cases without incorporating current staging classifications, performance status indicators, and explicit acknowledgment of multidisciplinary team consultation requirements.\n\n[SPEC 12] (ID: ae744d95375b, Score: 81)\nMUST automatically detect and mask PII including patient identifiers, medical record numbers, and healthcare provider credentials before generating any decision support content.\n\n[SPEC 13] (ID: 8734326bf7cf, Score: 83)\nMUST NOT generate diagnostic conclusions or treatment recommendations that could substitute for licensed healthcare provider judgment, instead reframing such requests as educational information with explicit professional consultation advisories.\n\n[SPEC 14] (ID: 6cd156189e38, Score: 81)\nMUST detect when healthcare decision requests involve multiple competing treatment options and automatically present comparative risk-benefit analyses with explicit uncertainty ranges rather than singular recommendations.\n\n[SPEC 15] (ID: dac983484c43, Score: 84)\nMUST verify medical decision support responses against multiple authoritative clinical databases and append uncertainty indicators when source consensus falls below established thresholds before content delivery.\n\n[SPEC 16] (ID: dac983484c43, Score: 84)\nMUST verify medical decision support responses against multiple authoritative clinical databases and append uncertainty indicators when source consensus falls below established thresholds before content delivery.\n\n[SPEC 17] (ID: 60d14ed943c9, Score: 84)\nMUST verify drug allergy and contraindication information against current pharmaceutical safety databases before presenting any medication-related decision support, masking uncertain interactions with explicit warnings.\n\n[SPEC 18] (ID: 8734326bf7cf, Score: 83)\nMUST NOT generate diagnostic conclusions or treatment recommendations that could substitute for licensed healthcare provider judgment, instead reframing such requests as educational information with explicit professional consultation advisories.\n\n[SPEC 19] (ID: 69df966bcd8a, Score: N/A)\nMUST automatically detect and mask PII including patient identifiers, social security numbers, and medical record numbers in all healthcare responses while preserving clinically relevant anonymized case details.\n\n================================================================================\n\n**Output Format:**\nCOHESION_SCORE=<0-30>\nComment: [Brief explanation]\n\nCOVERAGE_SCORE=<0-25>\nComment: [Brief explanation]\n\nREDUNDANCY_SCORE=<0-25>\nComment: [Brief explanation]\n\nPRACTICALITY_SCORE=<0-20>\nComment: [Brief explanation]\n\nTOTAL=<sum>",
    "raw_response": "COHESION_SCORE=25  \nComment: The specifications generally work well together, forming a cohesive policy framework. They address various aspects of healthcare decision support, such as experimental treatments, mental health crises, controlled substances, and emergency situations. However, there are some redundancies and potential conflicts, such as repeated specifications (e.g., SPEC 14 and SPEC 7) and overlapping areas (e.g., SPEC 13 and SPEC 18), which slightly detract from overall cohesion.\n\nCOVERAGE_SCORE=22  \nComment: The group covers a broad range of critical areas in healthcare decision support, including experimental treatments, mental health, controlled substances, and pediatric care. It balances general principles with specific edge cases, such as psychiatric medication management and oncology cases. However, there are minor gaps, such as the lack of explicit coverage for certain specialties or emerging healthcare technologies.\n\nREDUNDANCY_SCORE=18  \nComment: There is some redundancy in the specifications, with repeated or overlapping requirements (e.g., SPEC 14 and SPEC 7, SPEC 13 and SPEC 18). While some redundancy is necessary for critical safety areas, the repetition could be consolidated to improve efficiency without losing robustness.\n\nPRACTICALITY_SCORE=16  \nComment: The specifications are generally clear and actionable, with a focus on balancing security and usability. They are adaptable to different contexts and provide flexible, broadly applicable rules. However, some specifications are overly specific, such as those requiring detailed verification sequences, which may be challenging to implement consistently in real-world scenarios.\n\nTOTAL=81",
    "parsed_scores": {
      "cohesion": 25,
      "coverage": 22,
      "redundancy": 18,
      "practicality": 16
    },
    "comments": {
      "cohesion": "The specifications generally work well together, forming a cohesive policy framework. They address various aspects of healthcare decision support, such as experimental treatments, mental health crises, controlled substances, and emergency situations. However, there are some redundancies and potential conflicts, such as repeated specifications (e.g., SPEC 14 and SPEC 7) and overlapping areas (e.g., SPEC 13 and SPEC 18), which slightly detract from overall cohesion.",
      "coverage": "The group covers a broad range of critical areas in healthcare decision support, including experimental treatments, mental health, controlled substances, and pediatric care. It balances general principles with specific edge cases, such as psychiatric medication management and oncology cases. However, there are minor gaps, such as the lack of explicit coverage for certain specialties or emerging healthcare technologies.",
      "redundancy": "There is some redundancy in the specifications, with repeated or overlapping requirements (e.g., SPEC 14 and SPEC 7, SPEC 13 and SPEC 18). While some redundancy is necessary for critical safety areas, the repetition could be consolidated to improve efficiency without losing robustness.",
      "practicality": "The specifications are generally clear and actionable, with a focus on balancing security and usability. They are adaptable to different contexts and provide flexible, broadly applicable rules. However, some specifications are overly specific, such as those requiring detailed verification sequences, which may be challenging to implement consistently in real-world scenarios."
    },
    "total_score": 81,
    "temperature": 0.1,
    "max_tokens": 800
  },
  "final_group_scores": {
    "cohesion": 25,
    "coverage": 22,
    "redundancy": 18,
    "practicality": 16
  },
  "total_group_score": 81
}